ZIIHERA 50 mg/mL
zanidatamab-hrii · INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · Jazz Pharmaceuticals, Inc.
Ziihera is a bispecific antibody injection used to treat HER2-positive gastric or gastroesophageal junction cancer. It works by targeting cancer cells that have high levels of the HER2 protein.
Key Facts
- Brand Name
- ZIIHERA
- Generic Name
- zanidatamab-hrii
- NDC Code (Product)
68727-950- Manufacturer
- Jazz Pharmaceuticals, Inc.
- Strength
- 50 mg/mL
- Dosage Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761416
- Drug Class
- Bispecific HER2-directed Antibody [EPC]
- Marketing Start
- 11/20/2024
Recall History
No Recall HistoryFrequently Asked Questions
What is ZIIHERA used for?
Ziihera is a bispecific antibody injection used to treat HER2-positive gastric or gastroesophageal junction cancer. It works by targeting cancer cells that have high levels of the HER2 protein.
Is ZIIHERA a controlled substance?
ZIIHERA is not classified as a controlled substance by the DEA.
What is the generic name for ZIIHERA?
The generic name for ZIIHERA is zanidatamab-hrii. There are no other listed brand versions of zanidatamab-hrii.
What is the NDC code for ZIIHERA 50 mg/mL?
The NDC (National Drug Code) for ZIIHERA 50 mg/mL is 68727-950, listed by Jazz Pharmaceuticals, Inc..
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)